Poplar Therapeutics: Valuation, Funding & Investors
A clinical-stage immunology company developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions. Its lead program, PHB-050, is a next-generation anti-IgE antibody with a triple-action mechanism designed to block IgE binding, rapidly reduce circulating IgE, and inhibit its production to address multiple atopic diseases.
Leadership & Board
- Current Number of Employees
- 7
- Current LinkedIn Followers
- 1,400
Latest Estimated Valuation
- Total Amount Raised
- $50M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $50M
- Latest Funding Round
- Series A
Employee Trend
Poplar Therapeutics had 7 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Poplar Therapeutics had 1,400 followers as of November 16, 2026. The number of followers increased by 5 (0.36%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 07, 2026 | Series A | $50.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| SR One | Series A |
| Platanus | Series A |
| Vida Ventures | Series A |
Similar Companies
A snapshot of private companies similar to Poplar Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis







